ozanimod: Clinical Trials

54 trials of ozanimod, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

24 completed, 11 terminated, 7 recruiting, 6 active not recruiting. 16 Phase 3, 11 Phase 1, 7 Phase 2, 7 Phase 4, 1 Not applicable.

By phase and status

Phase	Trials	Status
Phase 3	16	Completed 8, Terminated 6, Recruiting 2
Phase 1	11	Completed 11
Phase 2	7	Completed 3, Recruiting 2, Terminated 2
Phase 4	7	Active not recruiting 2, Terminated 2, Withdrawn 2, Recruiting 1
Not applicable	1	Completed 1

Follow ozanimod: new trials by email Literature Review of ozanimod trials Research Report on ozanimod

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia Ozanimod - Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy		Recruiting	Bristol-Myers Squibb	15	2026-06-04	2026-07-29
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population Non-Interventional Study - Ulcerative Colitis		Active not recruiting	Pfizer	4000	2026-04-01	2026-10-15
Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis Ozanimod, Azathioprine - Ulcerative Colitis (UC)		Recruiting	Bristol-Myers Squibb	150	2026-01-29	2026-05-18
Ozanimod in Patients With Alzheimer's Disease Ozanimod, Conventional medication - Alzheimer Disease	Phase 2	Recruiting	ChenXiaoChun	40	2025-08-13	2026-07-27
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis Ozanimod, Fingolimod, Placebo - Multiple Sclerosis, Relapsing-Remitting	Phase 3	Recruiting	Bristol-Myers Squibb	194	2025-04-08	2026-09-10
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants Ozanimod, Conventional therapy, Advanced therapy - Ulcerative Colitis		Active not recruiting	Bristol-Myers Squibb	2828	2024-08-26	2024-10-01
Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ Study Ozanimod Oral Capsule - Ulcerative Colitis	Phase 4	Withdrawn	Geert D'Haens		2024-08-01	2024-09-19
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod Ozanimod - Relapsing Multiple Sclerosis	Phase 4	Recruiting	University of Colorado, Denver	100	2024-07-29	2025-09-18
Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS Ozanimod - Multiple Sclerosis	Phase 4	Withdrawn	The University of Texas at Dallas		2024-06-01	2024-08-09
A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis BMS-986374 - Relapsing Multiple Sclerosis	Phase 4	Active not recruiting	Bristol-Myers Squibb	84	2024-05-15	2025-04-16
A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea Ozanimod - Ulcerative Colitis		Recruiting	Bristol-Myers Squibb	3000	2024-04-19	2024-08-22
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success Ozanimod, TNF Inhibitor, Steroids - Ulcerative Colitis		Unknown	Insel Gruppe AG, University Hospital Bern	240	2023-09-06	2023-12-06
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy Ozanimod - Crohn Disease	Phase 2 / Phase 3	Terminated	Bristol-Myers Squibb	5	2023-08-22	2025-04-22
Define Predictors of Response to Ozanimod in UC Discovering Biomarkers in the Management of Ulcerative Colitis Ozanimod - Ulcerative Colitis		Withdrawn	Beth Israel Deaconess Medical Center		2023-04-12	2025-06-04
Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis. Ozanimod Oral Capsule - Multiple Sclerosis	Phase 4	Terminated	I.R.C.C.S. Fondazione Santa Lucia	30	2023-01-31	2025-01-15
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice Ozanimod - Colitis, Ulcerative	Phase 4	Terminated	Bristol-Myers Squibb	139	2022-12-16	2026-02-10
A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC) Ozanimod, Placebo - Ulcerative Colitis	Phase 3	Terminated	Bristol-Myers Squibb	131	2022-12-09	2025-03-26
A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative Colitis Ozanimod - Colitis, Ulcerative		Terminated	Bristol-Myers Squibb	175	2022-05-30	2025-07-02
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis Ozanimod - Colitis, Ulcerative	Phase 2 / Phase 3	Recruiting	Bristol-Myers Squibb	120	2022-05-30	2026-10-20
Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients Ozanimod - Fatigue, Multiple Sclerosis		Terminated	Brigham and Women's Hospital	26	2022-04-01	2025-11-28

ozanimod: Clinical Trials

54 trials of ozanimod, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

By phase and status

Trials newest first · largest first

Conditions studied

Sponsors

Countries

Top investigators

Results publications

NIH funding